Drug Profile
CLR 4001
Alternative Names: CJH 1; CLR4001; CRL 400Latest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator Clera
- Class Antiparkinsonians
- Mechanism of Action Dopamine receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 21 Aug 2019 Discontinued - Phase-II for Parkinson's disease in Canada (PO)
- 05 Feb 2016 Phase-IIa development is ongoing in Canada
- 01 Sep 2012 Phase-II clinical trials in Parkinson's disease in Canada (PO)